Our news - IRCCS

Events Studies on data Published on 17/11/2025

ASH 2025 : oral communication for Dr. Stéphanie CORDEIL

VACARME : Analysis of humoral protection at baseline and after vaccination in patients with refractory/relapsed lymphoma and myeloma treated with CD19 and BCMA CAR T-cells.

Clinical trials Events Published on 17/11/2025

Oral presentation for Dr. Pierre SESQUES at ASH 2025

Outcome of patients with large B-cell lymphoma relapsing after second-line CAR-t: Insights from the descar-t registry

Clinical trials Published on 17/11/2025

HLA diversity is associated with TKI response and treatment-free remission in chronic myeloid leukemia

Charles Toulemonde, Valérie Dubois, Christophe Bouvier, Alexandre Ridao, Marie-Claire Archier, Marie Balsat, Sophie Ducastelle, Fiorenza Barraco, Gaelle Fossard, Julie Hildt, Julien Bollard, Mauricette Michallet, Hélène Labussière-Wallet, Sandrine Hayette, Franck-Emmanuel Nicolini, Vincent Alcazer

Events Studies on data Published on 17/11/2025

Dr. Vincent Alcazer will present an oral communication at ASH 2025

Presentation ID 76 : A machine learning approach identifies a transcriptomic signature predicting treatment-free remission in chronic myeloid leukemia.

Events Published on 04/11/2025

SAVE THE DATE Post-regional ASH: March 6, 2026

Provisional program, subject to change: 9:00 AM: Welcome of participants: Prof. Bachy, Dr. Golfier 9:15 AM: Updates in allogeneic transplantation: Dr. Labussière, Prof. Bay, Dr. Cornillon 9:45 AM: Updates in AML and ALL: Dr. Heiblig, Dr. Carre, Dr. Balsat Coffee break 11:15 AM: Updates in myelodysplastic syndromes: Dr. Fossard, Prof. Park 11:45 AM: Updates in lymphomas: Prof. Ghesquieres, Dr. Carras, Dr. Sesques, Dr. Fouillet Lunch break 2:00 PM: Updates in benign hematology: Prof. Garban 2:15 PM: Updates in PNH, aplasias, and myeloproliferative syndromes: Dr. Alcazer, Dr. Barraco 3:15 PM: Updates in multiple myeloma: Dr. Karlin, DR. Lazareth, DR. Chalayer Coffee Break 3:45 PM: News in the LLC: Prof. Guiez, Dr. Ferrant 4:15 PM: Conclusions and Acknowledgments: Prof. Bachy

Studies on data Published on 30/06/2025

Presentation of 2 posters at the LUGANO 2025 congress

Pr. Hervé GHESQUIÈRES: Synthetic control arm from clinical trial and real-world cohorts from LYSA group for untreated older classical Hodgkin lymphoma for innovative clinical trial designs Dr. Estelle BOURBON: Impact of Response to Holding/Bridging Therapy in Second-line DLBCL Patients Treated with Axicabtagene ciloleucel: a LYSA Study from the French DESCAR-T Registry

Clinical trials Events Published on 30/06/2025

Pr Hervé GHESQUIÈRES in the spotlight: oral participation at LUGANO 2025

Final analysis of the Lysa Phase II TIRHOL BGB-A317-210 study: TISLELIZUMAB, an anti-PD-1 antibody in patients with relapsed or refractory classical Hodgkin lymphoma.

Clinical trials Events Published on 30/06/2025

Pr Emmanuel BACHY : communication at LUGANO congress

Extended follow-up results for GOLCADOMIDE + rituximab in patients with relapsed/refractory (R/R) DLBCL in the Phase 1/2 CC-99282-NHL-001 study (NCT03930953).